Sanofi Completes Acquisition of Blueprint Medicines

Sanofi has completed its acquisition of Blueprint Medicines, a US-based biotech firm. The company has also extended its tender offer for Blueprint Medicines by one day. Sanofi has also entered into an agreement with Thermo Fisher Scientific to sell its manufacturing site in New Jersey. Additionally, Sanofi has received fast-track designation from the FDA for its treatment for geographic atrophy due to age-related macular degeneration.

Sanofi has extended its tender offer for Blueprint Medicines Corporation by one day, providing shareholders with additional time to participate in the offer. The offer, initially set to expire at 23:59 EDST on July 16, 2025, has been extended until 17:00 EDST on July 17, 2025 [1]. As of the extension, approximately 29,742,419 shares, representing 45.85% of the total outstanding shares of Blueprint, have been validly tendered. Additionally, 23,400,152 shares have been tendered by notice of guaranteed delivery, accounting for 36.08% of the outstanding shares [1].

Sanofi has also completed its acquisition of Blueprint Medicines, a US-based biotech firm. The acquisition is part of Sanofi's strategy to expand its presence in the biotechnology sector and strengthen its pipeline of innovative treatments [1]. The tender offer is being made pursuant to the terms and conditions described in the offer to purchase, dated June 17, 2025, and is conditioned upon the fulfillment of certain conditions, including the tender of a majority of the then-outstanding shares of Blueprint’s common stock [1].

In addition to the tender offer extension, Sanofi has entered into an agreement with Thermo Fisher Scientific to sell its manufacturing site in New Jersey. The sale is part of Sanofi's broader effort to streamline its operations and focus on its core competencies in biopharmaceuticals [1].

Sanofi has also received fast-track designation from the FDA for its treatment for geographic atrophy due to age-related macular degeneration. The fast-track designation is designed to expedite the review and approval process for drugs that address serious or life-threatening conditions and provide a significant advantage in the treatment of these conditions [1].

These developments highlight Sanofi's ongoing commitment to innovation and growth in the biopharmaceutical sector, as well as its strategic partnerships and regulatory achievements.

References:
[1] https://www.sanofi.com/en/media-room/press-releases/2025/2025-07-17-05-00-00-3116948